Dengue Virus IgM µ-capture ELISA Kit (Human)

Cat# OKNA00132

Size : 96Wells

Brand : Aviva Systems Biology

Contact local distributor :


Phone : +1 850 650 7790

Datasheets/ManualsClick here to download product manual. As variation between lots may occur, always reference the lot-specific manual received with each kit.
Product Info
Predicted Species ReactivityHuman
ELISA Kit Detection MethodColorimetric, OD450 nm
ELISA Kit Duration~3 Hours
ELISA Kit PrincipleAviva Systems Biology Dengue Virus IgM u-capture ELISA Kit (Human) (OKNX00132) is based on standard reverse capture sandwich enzyme-linked immuno-sorbent assay technology. Dengue Virus u-capture antigen has been pre-coated and blocked in a 96-wellplate (12 x 8 Well Strips). Standards or test samples are added to the wells, incubated and washed. An HRP conjugated detector antibody specific for Human IgM is added, incubated and followed by washing. An enzymatic reaction is produced through the addition of substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration is read by absorbance at 450 nm and is qualitatively proportional to the amount of sample anti-Dengue Virus u-capture IgM captured the in well.
ELISA Kit Reproducibility
MetricSample Typen=CV%
Inter-AssaySerum #21220.024.8
Inter-AssaySerum #4128.966.2
Inter-AssaySerum #5125.325.8
Intra-AssaySerum #1230.533.2
Intra-AssaySerum #2241.0192.4
Intra-AssaySerum #3240.9862.8
ELISA Kit Component
ComponentAmount
Dengue Virus u-capture IgM Well Plate96 Wells (12 x 8 Well Strips)
IgM Sample Diluent1 x 100 mL
Stop Solution1 x 15 mL
20X Wash Solution1 x 50 mL
Anti-IgM HRP Conjugate1 x 20 mL
TMB Substrate1 x 15 mL
Dengue Virus u-capture Positive Control1 x 2 mL
Dengue Virus u-capture Cut-Off Control1 x 3 mL
Dengue Virus u-capture Negative Control1 x 2 mL
Reconstitution and StorageStore as indicated in product manual.
Sample TypeSerum, Plasma
SensitivitySensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: > 98%
SpecificitySpecificity is determined as the probability of the assay indicating a negative score in samples absent of the specific analyte: > 97.5%
Assay InfoAssay Methodology: Quantitative Reverse Capture Sandwich ELISA
Alias SymbolsDENV
Protein NameDengue Virus u-capture IgM
Description of TargetDengue fever, also known as breakbone fever, is an infectious tropical disease caused by the dengue virus and transmitted by mosquitoes. Dengue fever virus (DENV) is a virus of the family Flaviviridae, genus Flavivirus and contains a single-stranded RNA genome with positive polarity. There are four serotypes of the virus, which are referred to as DENV-1, DENV-2, DENV-3 and DENV-4. The geographical distribution is around the equator, particularly Latin America, Central Africa, India, Southeast Asia, Western Pacific and South of the USA. Dengue viruses are transmitted to humans through the bites of infective female yellow fever mosquitoes (Stegomyia aegypti, formerly Aedes aegypti). The mosquitoes generally acquire the virus while feeding on the blood of an infected person. After virus incubation for eight to ten days, an infected mosquito is capable, during probing and blood feeding, of transmitting the virus for the rest of its life. Yellow fever mosquitoes are well adapted to living in close proximity to humans, and to feeding off people rather than other vertebrates. They prefer to lay their eggs in artificial water containers, such as flower vases, uncovered barrels, buckets and discarded tires. The incubation period ranges from 3-14 days, but most often it is 4-7 days. Typically, people infected with dengue virus are asymptomatic or only have symptoms of a common cold. The characteristic symptoms of dengue are sudden-onset fever (up to 40 C) with intense headache (especially behind the eyes), and muscle and joint pain. In combination with a skin rash this symptoms are known as the „dengue triad“. This usually lasts 3-7 days. In some patients the disease proceeds to a critical phase. Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS) occur in less than 5 % of all cases of dengue. About 1-5 % of severe cases are fatal. In individual epidemics the case-fatality rate may reach up to 15 %. Infection with one serotype is believed to produce lifelong immunity to that serotype but only short term protection against the others. Secondary infection with a different serotype may result in severe clinical manifestations. There is no vaccination available.

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
EA100939
 1x96wells